ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Envelope protein

Envelope protein

概要

Name:Recombinant envelope protein
Target Synonym:env,Submitted name: Recombinant envelope protein,Viral Envelope Proteins
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
ENN-D5244 Dengue virus DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (MALS verified)
ENN-D5244-sds
ENN-C5128 SARS-CoV-2 SARS-CoV-2 (COVID-19) Envelope protein, GST,His Tag
ENN-C5128-structure
ENN-C5128-sds
ACRO Quality

生物活性データの一部

ENN-D5244-MALS-HPLC
Envelope protein MALS images

The purity of DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (Cat. No. ENN-D5244) is more than 85% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.

ENN-D5244-ELISA
 Envelope protein ELISA

Immobilized DENV2 (strain Thailand/16681/1984) Envelope Protein, His Tag (Cat. No. ENN-D5244) at 1 μg/mL (100 μL/well) can bind Human Anti-E(DENV) Antibody EDE2 A11,Human IgG1 | Human Kappa with a linear range of 1-39 ng/mL (QC tested).

Synonym Name

Envelope protein,Env polyprotein,Envelope glycoprotein,env

Background

The SARS-CoV-2 is composed of a double-layered lipid envelope, including Spike glycoprotein (S), Envelope protein (E), Membrane glycoprotein (M), and Nucleocapsid protein (Nucleocapsid protein, N). Among them, The amino acid sequence of the SARS-CoV-2 envelope protein is 95% identical of the SARS envelope protein.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tecovirimat SIGA-246; ST-246 Approved Siga Technologies Inc Tpoxx United States Smallpox Siga Technologies Inc 2018-07-13 Smallpox; Cowpox; Vaccinia; Poxviridae Infections; Monkeypox Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Temelimab GNN-001; GENHP-01; GNbAC-1 Phase 2 Clinical Geneuro Sa Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Coronavirus Disease 2019 (COVID-19); Multiple Sclerosis Details
PGDM-1400 PGDM-1400; PGDM1400LS Phase 2 Clinical International Aids Vaccine Initiative HIV Infections; Acquired Immunodeficiency Syndrome; Retroviridae Infections; Sexually Transmitted Diseases, Viral; HIV Seropositivity Details
VIS-513 VIS-513; Ab-513 Phase 1 Clinical Otsuka Pharmaceutical Co Ltd, Serum Institute Of India Ltd, Visterra Inc Dengue Details
Targeting HIV-1 Env gp140 antibodies Phase 2 Clinical National Institute Of Allergy And Infectious Diseases (Niaid) HIV Infections Details

This web search service is supported by Google Inc.

totopphone